Last reviewed · How we verify
Neoantigen mRNA Vaccine
Neoantigen mRNA Vaccine is a Biologic drug developed by Second Affiliated Hospital of Guangzhou Medical University. It is currently in Phase 1 development.
At a glance
| Generic name | Neoantigen mRNA Vaccine |
|---|---|
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer (PHASE1)
- XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer (NA)
- Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer (PHASE1)
- Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL (PHASE1)
- Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer (EARLY_PHASE1)
- Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors (EARLY_PHASE1)
- XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer (NA)
- Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neoantigen mRNA Vaccine CI brief — competitive landscape report
- Neoantigen mRNA Vaccine updates RSS · CI watch RSS
- Second Affiliated Hospital of Guangzhou Medical University portfolio CI
Frequently asked questions about Neoantigen mRNA Vaccine
What is Neoantigen mRNA Vaccine?
Neoantigen mRNA Vaccine is a Biologic drug developed by Second Affiliated Hospital of Guangzhou Medical University.
Who makes Neoantigen mRNA Vaccine?
Neoantigen mRNA Vaccine is developed by Second Affiliated Hospital of Guangzhou Medical University (see full Second Affiliated Hospital of Guangzhou Medical University pipeline at /company/second-affiliated-hospital-of-guangzhou-medical-university).
What development phase is Neoantigen mRNA Vaccine in?
Neoantigen mRNA Vaccine is in Phase 1.